Tricagrelor for Bleeding Complications

Phase-Based Progress Estimates
Mayo Clinic in Rochester, Rochester, MNBleeding ComplicationsTricagrelor - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether it is safe to reduce the time patients are on two blood-thinning medications after having a coronary stent placed.

Eligible Conditions
  • Bleeding Complications

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Through study completion, approximately 90 days.

Day 90
Ischemic risk post-PCI in high bleed risk patients with genotype-guided single antiplatelet therapy

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Conventional Therapy
1 of 2
Genotype-Guided Therapy
1 of 2

Active Control

Experimental Treatment

150 Total Participants · 2 Treatment Groups

Primary Treatment: Tricagrelor · No Placebo Group · Phase 4

Genotype-Guided TherapyExperimental Group · 2 Interventions: Tricagrelor, Prasugrel · Intervention Types: Drug, Drug
Conventional Therapy
ActiveComparator Group · 1 Intervention: Clopidogrel · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, approximately 90 days.

Who is running the clinical trial?

Mayo ClinicLead Sponsor
2,952 Previous Clinical Trials
3,447,635 Total Patients Enrolled
Mandeep Singh, MDPrincipal InvestigatorMayo Clinic
5 Previous Clinical Trials
240 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many individuals have enrolled in the research trial?

"Confirmed. The clinical trial is actively recruiting according to the data hosted on, which was first posted on March 29th 2022 and most recently updated October 24th 2022. 150 prospective participants are needed from a single medical facility." - Anonymous Online Contributor

Unverified Answer

Is enrollment in this research study still a viable option for those seeking treatment?

"Affirmative. Details obtained from demonstrate that the clinical trial, which was first advertised on March 29th 2022, is actively recruiting patients. 150 volunteers are required at a single location to participate in this research endeavour." - Anonymous Online Contributor

Unverified Answer

Is the drug Tricagrelor officially certified by the FDA?

"As this is a phase 4 trial, there are numerous studies that have validated tricagrelor's safety and efficacy; thus we assign it a score of 3." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.